Vi­vo Cap­i­tal bags $635M for its new biotech pub­lic com­pa­ny fund

Vi­vo Cap­i­tal has raised a whop­ping $635 mil­lion for a new biotech pub­lic com­pa­ny fund — pret­ty much per­fect tim­ing for an in­vest­ment group with deep roots in the transpa­cif­ic re­gion and a big in­ter­est in IPOs and both small and mid-sized pub­lic com­pa­nies.

The Vi­vo Op­por­tu­ni­ty Fund was over­sub­scribed, which may not come as too much of a sur­prise. The group has of­fices in Pa­lo Al­to, Bei­jing, Shang­hai and Taipei and a track record that in­cludes a long list of pri­vate and pub­lic biotech fi­nanc­ings.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.